



**BIOGEN AUSTRALIA PTY LTD**  
ACN 095 760 115

**Modern Slavery Statement**  
Calendar Year 2020

Biogen Australia Pty Ltd is a subsidiary of Biogen Inc, and has its main office in Macquarie Park, NSW, Australia.

The attached Biogen Anti-Slavery and Human Trafficking Statement for the Calendar Year 2020 (hereafter, the 'Statement') describes Biogen's global commitment, approach and measures taken to combat modern slavery and human trafficking. The Statement also covers the operations and activities of Biogen Australia Pty Ltd as a reporting entity under the Modern Slavery Act 2018 (Commonwealth) and is intended to address applicable disclosure requirements under that Act.

I confirm that the Statement was approved for reporting purposes under the Modern Slavery Act in respect of the Calendar Year 2020 for Biogen Australia Pty Ltd, by unanimous resolution of the Board of Directors of Biogen Australia Pty Ltd made on 22 June 2021 (AEST).

A handwritten signature in black ink, appearing to read "Kylie Bromley", written over a horizontal line.

Kylie Bromley  
**Managing Director**

Biogen Australia Pty Ltd

13 July 2021

## Biogen Anti-Slavery and Human Trafficking Statement

At Biogen, we have a long-standing commitment to corporate responsibility. This includes upholding human rights and ensuring that modern slavery (in all its forms) is not tolerated within our global business or our supply chain. Biogen has a zero-tolerance approach to modern slavery wherever we conduct business around the world.

This statement describes Biogen's global commitment, approach and measures taken to combat modern slavery and human trafficking. In addition, this statement is intended to address any applicable disclosure requirements of the Commonwealth Modern Slavery Act 2018 (Australia), Modern Slavery Act 2015 (United Kingdom), the California Transparency in Supply Chains Act of 2010 (California, USA), and other similar laws and regulations, to the extent applicable to Biogen's global business activities or any portion thereof, relating to our efforts to combat modern slavery and human trafficking.

### Organization, structure, business, and supply chains

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology, and neuropathic pain.

With approximately 9,100 employees worldwide, Biogen operates globally including our global headquarters in Cambridge, MA, USA; international headquarters in Baar, Switzerland; and world-class manufacturing facilities in Research Triangle Park, NC, USA; and Solothurn, Switzerland. Our products are distributed worldwide, and we also make use of contract manufacturing organizations (CMOs) and external suppliers for product inputs and packaging.

### Policies related to slavery and human trafficking

Biogen is committed to conducting business in accordance with the highest degree of integrity and in compliance with applicable laws, which includes recognizing and respecting human rights. Biogen prohibits all forms of slavery and human trafficking within our supply chains and business operations.

In every country in which we operate, Biogen follows all laws, regulations, and international conventions related to human rights, including the *International Labor Office Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy* and the *Organization for Economic Co-operation and Development (OECD) Guidelines for Multinational Enterprises*. Our human rights position is also guided by the *U.N. Universal Declaration of Human Rights* and *U.N. Guiding Principles for Business and Human Rights*.

This commitment is reflected through our [Code of Business Conduct](#) and [Human Rights Position Statement](#), which together, set forth our code of ethics and expectations regarding responsible business conduct. These documents provide information about the standards of integrity that Biogen requires all employees, officers, and subsidiaries to follow, including standards relating to fair treatment and diversity, anti-harassment and bullying, human trafficking, and forced, compulsory, bonded or child labor.

Biogen expects that our suppliers adhere to the Code of Business Conduct, which provides guidance and requirements for doing business with Biogen. In addition, suppliers are also required to comply with the terms and conditions of applicable contracts and purchase orders entered into by both parties. Each supplier doing business with Biogen under

these terms and conditions agrees it will comply with all applicable laws and regulations in its performance of the contract. Biogen does not currently require a separate certification in addition to these contractual provisions.

**Areas of business risk for slavery and trafficking**

While we have owned operations, contract manufacturers, suppliers, and sales and distribution in numerous countries around the world, the large majority of our operations and supply chain partners are located in more economically developed countries that our own and independent assessments (such as the U.S. Department of State’s *Trafficking in Persons* report) have found to be at lower risk for human rights violations including slavery and human trafficking.

**Due diligence process, performance indicators, and effectiveness related to slavery and trafficking in our own business and supply chain**

Biogen monitors the environmental, social, and governance risks of our supply chain, including human trafficking risks, based upon the industry in which we operate and the geographic locations in which we conduct business and/or obtain materials and services. We do this through a process of reviewing country risk profiles for corruption and human trafficking risks published by independent third-party expert organizations and providing added diligence on specific areas or suppliers as needed based on this assessment. Our risk assessment process for 2020 indicated low risk of human rights issues or violations in our supply chain. A summary of our due diligence process, key performance indicators, and results of this supply chain risk assessment is reported in our [2020 Year in Review](#).

In addition to our own due diligence process, Biogen is a member of the Pharmaceutical Supply Chain Initiative (PSCI), an organization made up of leading global pharmaceutical companies that focuses on increasing the capabilities and responsibility of our supply chains. The PSCI has developed and shared with industry suppliers our Principles for Responsible Supply Chain Management, which include prohibitions against forced and child labor, along with other expectations regarding responsible labor, governance, and environmental practices. More details on the PSCI and these Principles can be found at <https://pscinitiative.org/home>.


**Training and capacity building on slavery and human trafficking prevention**

All Biogen employees are trained on our Code of Business Conduct upon hire and undergo mandatory annual refresher training thereafter. This training includes information about our issue reporting hotlines and other tools and familiarizes our team with the system that allows us to address, resolve, and track any human rights or other issues that may arise.

Biogen also provides information and training to its Global Procurement Team directly involved with the selection of new suppliers and the ongoing management of current suppliers.

---

Michel Vounatsos  
Director and Chief Executive Officer  
Biogen Inc.

  
\_\_\_\_\_  
Signature

June 2, 2021  
\_\_\_\_\_  
Date